Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

NCT05653882 is registered in ClinicalTrials.gov with Asher Biotherapeutics, Inc. as lead sponsor.

NCT NCT05653882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05653882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Asher Biotherapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 4, 2023
Completion date
May 31, 2027
Enrollment
552 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, non small cell lung cancer, renal cell carcinoma, solid tumor, squamous cell carcinoma of head and neck